Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion

Novo Nordisk has agreed to acquire Akero Therapeutics for up to $5.2 billion, offering $54 per share upfront plus a $6 contingent value right tied to FDA approval of efruxifermin for MASH, representing a 16.2% premium. This acquisition provides Novo Nordisk with Akero's experimental liver disease drug, efruxifermin, aligning with the Danish drugmaker's strategic focus on cardiometabolic conditions to revive growth and compete with Eli Lilly. Akero's shares surged over 19% in premarket trading on the news.

Analysis

Novo Nordisk said on Thursday it agreed to buy Akero Therapeutics for up to $5.2 billion, giving the Danish drugmaker access to the U.S.-based company's experimental liver disease drug. The maker of blockbuster obesity drug Wegovy is pressing ahead with a sweeping restructuring in a bid to revive sales growth and fend off intense competition from U.S. rival Eli Lilly. Under the deal, Novo would pay Akero shareholders $54 per share upfront in cash, which represents a premium of about 16.2% to Akero's last close of $46.49 on Wednesday. The Danish drugmaker will also pay an additional $6 per share upon full U.S. approval of efruxifermin for treatment of compensated cirrhosis due to MASH by June 30, 2031, the companies said. Akero's shares rose over 19% in premarket trading. Novo's new CEO, Mike Doustdar, who took the reins in July, last month announced the company would cut 9,000 jobs. Doustdar has said the company will retain a tight focus on developing the next generation of highly effective obesity and diabetes drugs, which can also be used to treat related cardiometabolic conditions such as MASH, rather than expanding into other disease areas. Akero's experimental drug, efruxifermin, is being studied in patients with severe scarring or cirrhosis due to a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH). Novo Nordisk has agreed to acquire Akero Therapeutics for up to $5.2 billion, comprising $54 per share upfront and a $6 contingent value right (CVR) tied to efruxifermin's U.S. FDA approval by June 30, 2031. This represents a 16.2% premium over Akero's prior close, leading to a premarket stock surge exceeding 19% for AKRO. The acquisition aligns with Novo Nordisk's (NVO) new CEO Mike Doustdar’s strategic pivot towards next-generation obesity, diabetes, and related cardiometabolic drugs, including MASH, amidst a significant restructuring involving 9,000 job cuts. This focus aims to revive sales growth and enhance competitiveness against rival Eli Lilly (LLY). Access to Akero’s experimental drug, efruxifermin, which targets severe MASH-related scarring or cirrhosis, critically reinforces Novo Nordisk’s pipeline. This addition strengthens NVO’s presence in a key adjacent market to its established obesity franchise, Wegovy, enabling broader portfolio synergy. This M&A move underscores Novo Nordisk’s proactive strategy to leverage capital for pipeline enhancement and secure future growth within its prioritized therapeutic areas. The company is actively executing on its strategic intent to leadership in the cardiometabolic space alongside internal optimization efforts.

Key Decisions for Investors

• Investors should assess Novo Nordisk's enhanced pipeline and strategic commitment to cardiometabolic conditions, considering its long-term growth prospects.
• Monitor the clinical development and regulatory pathway of efruxifermin, particularly concerning the CVR's conditions for FDA approval by 2031.
• Evaluate the evolving competitive landscape within the obesity, diabetes, and MASH treatment sectors, especially in relation to Eli Lilly's market position.